126 related articles for article (PubMed ID: 38502572)
1. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo.
Sakai K; Kato D; Yoshinaka J; Takahashi Y; Ikeda N; Aoki S; Iguchi T; Ishikawa S; Yamagishi N; Shimamura S; Nakagawa T
Vet Comp Oncol; 2024 Jun; 22(2):230-238. PubMed ID: 38502572
[TBL] [Abstract][Full Text] [Related]
2. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
[TBL] [Abstract][Full Text] [Related]
3. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N
Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405
[TBL] [Abstract][Full Text] [Related]
7. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
La Monica S; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Digiacomo G; Flammini L; Barocelli E; Minari R; Naldi N; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2017 Dec; 36(1):174. PubMed ID: 29202823
[TBL] [Abstract][Full Text] [Related]
9. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
14. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
15. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
Wang H; Wang W; Xu Y; Yang Y; Chen X; Quan H; Lou L
Cancer Sci; 2017 Jul; 108(7):1458-1468. PubMed ID: 28388007
[TBL] [Abstract][Full Text] [Related]
16. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
Skeie M; Nikolaysen F; Chitano Y; Stang E
J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
[TBL] [Abstract][Full Text] [Related]
18. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
[TBL] [Abstract][Full Text] [Related]
19. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
20. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Menderes G; Bonazzoli E; Bellone S; Altwerger G; Black JD; Dugan K; Pettinella F; Masserdotti A; Riccio F; Bianchi A; Zammataro L; de Haydu C; Buza N; Hui P; Wong S; Huang GS; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Oct; 147(1):145-152. PubMed ID: 28705408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]